We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

68 hedge funds and large institutions have $398M invested in KalVista Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

52% more capital invested

Capital invested by funds: $261M → $398M (+$137M)

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

19% more funds holding

Funds holding: 57 → 68 (+11)

3.33% more ownership

Funds ownership: 77.28% → 80.61% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
68
Holders Change
+11
Holders Change %
+19.3%
% of All Funds
1.47%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
17
Increased
20
Reduced
16
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$23.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.9M
3
Millennium Management
Millennium Management
New York
+$2.09M
4
O
OrbiMed
New York
+$1.96M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.41M

Top Sellers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
-$15.5M
2
VMI
VHCP Management III
New York
-$6.81M
3
BI
BVF Inc
California
-$4.99M
4
VMI
VHCP Management II
New York
-$4.03M
5
BC
Broadfin Capital
New York
-$2.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
51
GSA Capital Partners
United Kingdom
$211K +$160K +7,371 New
Bank of New York Mellon
52
Bank of New York Mellon
New York
$204K +$155K +7,128 New
MWNA
53
Marshall Wace North America
New York
$175K +$133K +6,126 New
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$166K +$28K +1,292 +29%
Bank of America
55
Bank of America
North Carolina
$164K +$28.9K +1,335 +30%
FQ
56
First Quadrant
California
$86K -$1.04K -48 -2%
TAM
57
Tiverton Asset Management
Delaware
$72K – – –
FCM
58
Flinton Capital Management
Pennsylvania
$37K – – –
TAM
59
Tyers Asset Management
Texas
$31K – – –
NA
60
Neuburgh Advisers
California
$24K – – –
PCM
61
Prelude Capital Management
New York
$20K +$2.17K +100 +17%
MCIM
62
Meadow Creek Investment Management
Georgia
$17K – – –
Federated Hermes
63
Federated Hermes
Pennsylvania
$14K +$4.44K +205 +72%
UBS Group
64
UBS Group
Switzerland
$14K +$10.5K +485 New
DWA
65
Dorsey Wright & Associates
California
$12K -$9.3K -429 -50%
VFA
66
Valeo Financial Advisors
Indiana
$4K – – –
TRCT
67
Tower Research Capital (TRC)
New York
$1K -$2.77K -128 -79%
AG
68
Advisor Group
Arizona
$1K – – –
BI
69
BVF Inc
California
– -$4.99M -252,693 Closed
BC
70
Broadfin Capital
New York
– -$2.83M -143,129 Closed
TI
71
Telemetry Investments
New York
– -$491K -24,883 Closed
OAM
72
Oxford Asset Management
United Kingdom
– -$236K -11,967 Closed
RQS
73
Ramsey Quantitative Systems
Kentucky
– -$35K -1,789 Closed
LC
74
Lindbrook Capital
California
– -$5K -300 Closed
1 2
3

KALV Hedge Fund Activity: Q1 2019 in Review

68 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2019, worth a combined $398M — up 52% from $261M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KALV positions and 6 closed out — a net gain of 11 holders — while 20 added to existing stakes and 16 trimmed.

The largest buyer was Polar Capital, adding an estimated $23.2M. The largest seller was SV Health Investors, cutting an estimated $15.5M.

  • 68 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2019, up from 57 in Q4 2018.
  • Funds reported $398M of KalVista Pharmaceuticals stock for Q1 2019, up 52% quarter-over-quarter.
  • 17 funds opened new KalVista Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of +11 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2019 was Polar Capital, an estimated $23.2M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2019 was SV Health Investors, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2019.